FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells

Table 1 Growth inhibition rate and apoptosis rate of each group of cells treated with different concentrations of cisplatin for different lengths of time

Group	Cases	Growth inhibition rate			Apoptosis rate
Group	Cases	24 h	48 h	72 h	24 h	48 h	72 h
pWPI-FOLR1-SKOV 3 (μg/ml)
1.8	12	8.86 ± 0.69	17.43 ± 0.91	30.29 ± 0.84	16.54 ± 2.58	24.84 ± 2.69	32.28 ± 2.97
3.6	12	18.52 ± 0.97	50.63 ± 1.31	64.28 ± 1.45	19.50 ± 2.71	50.08 ± 3.85	65.68 ± 4.03
7.2	12	32.24 ± 1.13	67.69 ± 1.24	79.38 ± 2.01	35.28 ± 3.59	71.44 ± 4.51	79.17 ± 4.58
pWPI-SKOV3 (μg/ml)
1.8	12	6.54 ± 0.45	9.73 ± 0.67	15.79 ± 0.32	10.08 ± 2.19	14.89 ± 2.58	15.32 ± 2.61
3.6	12	12.89 ± 0.73	27.24 ± 0.85	38.21 ± 0.89	12.39 ± 2.06	27.61 ± 2.77	39.83 ± 3.19
7.2	12	19.26 ± 0.89	56.21 ± 1.04	69.77 ± 1.43	24.19 ± 2.78	58.80 ± 4.11	65.63 ± 3.91
SKOV3 (μg/ml)
1.8	12	5.67 ± 0.48	8.35 ± 0.61	14.6 ± 0.45	9.27 ± 1.86	14.36 ± 2.56	17.72 ± 2.67
3.6	12	13.95 ± 0.56	24.59 ± 0.78	41.48 ± 0.75	11.27 ± 1.98	23.58 ± 2.49	40.64 ± 3.28
7.2	12	16.25 ± 0.67	57.73 ± 1.18	67.42 ± 1.51	23.62 ± 3.12	54.87 ± 4.10	68.64 ± 4.35

ISSN: 1757-2215